Cerity Partners’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Cerity Partners’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,950	Closed	-$26K	–	1259
2022 Q1	$26K	Hold	15,950	–	–	﹤0.01%	928
2021 Q4	$38K	Sell	15,950 -50	-0.3%	-$204	﹤0.01%	1007
2021 Q3	$87K	Sell	16,000 -2,800	-15%	-$17.4K	﹤0.01%	670
2021 Q2	$140K	Buy	18,800 +300	+2%	+$2.13K	﹤0.01%	689
2021 Q1	$150K	Buy	+18,500	New	+$202K	﹤0.01%	674

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cerity Partners's KLDO Position: Q2 2022 in Review

Cerity Partners sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 15,950 shares — an estimated $26K sold.

Cerity Partners first reported a position in KLDO in Q1 2021 and held it in 5 quarters. The position peaked at $150K in Q1 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Cerity Partners reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Cerity Partners sold 15,950 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $26K.
Cerity Partners first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Cerity Partners's Kaleido Biosciences, Inc. Common Stock position peaked at $150K in Q1 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Cerity Partners's 13F filing for Q2 2022, filed 10 Aug 2022.